The chemokine fractalkine (CX3CL1) and its receptor CX3CR1 play critical roles in inflammation-induced angiogenesis and tumorigenesis. CX3CL1, a unique molecule combining chemotactic and adhesive properties, exists in two forms: membrane-bound (mFKN) and soluble (sFKN). mFKN facilitates leukocyte adhesion to endothelial cells, promoting angiogenesis, while sFKN acts as a chemoattractant for immune cells. Both forms signal through CX3CR1, a G protein-coupled receptor, which is the sole known receptor for CX3CL1. CX3CR1 is involved in various cellular processes, including adhesion, migration, and survival, and its signaling pathways are crucial for immune responses and tumor progression. CX3CL1 is upregulated by hypoxia and inflammatory cytokines, making it a key angiogenic factor in the tumor microenvironment. The CX3CL1/CX3CR1 axis influences cell adhesion, apoptosis, and migration, contributing to both pro- and anti-tumor effects. Inflammation and angiogenesis are closely linked, with chronic inflammation promoting angiogenesis through hypoxia and cytokine release. The CX3CL1/CX3CR1 axis enhances this process by activating signaling pathways such as NF-κB, PI3K/Akt, and MAPK, which regulate angiogenesis and tumor growth. The CX3CR1 receptor is expressed in various cell types, including immune cells and endothelial cells, and its activity is modulated by factors such as NF-κB, which controls CX3CL1 expression. The interplay between inflammation and angiogenesis is complex, with CX3CL1/CX3CR1 signaling playing a pivotal role in both processes. Dysregulation of this axis can lead to pathological conditions, including cancer metastasis and poor prognosis. Understanding the mechanisms of CX3CL1/CX3CR1 signaling is essential for developing therapeutic strategies targeting inflammation and tumor progression.The chemokine fractalkine (CX3CL1) and its receptor CX3CR1 play critical roles in inflammation-induced angiogenesis and tumorigenesis. CX3CL1, a unique molecule combining chemotactic and adhesive properties, exists in two forms: membrane-bound (mFKN) and soluble (sFKN). mFKN facilitates leukocyte adhesion to endothelial cells, promoting angiogenesis, while sFKN acts as a chemoattractant for immune cells. Both forms signal through CX3CR1, a G protein-coupled receptor, which is the sole known receptor for CX3CL1. CX3CR1 is involved in various cellular processes, including adhesion, migration, and survival, and its signaling pathways are crucial for immune responses and tumor progression. CX3CL1 is upregulated by hypoxia and inflammatory cytokines, making it a key angiogenic factor in the tumor microenvironment. The CX3CL1/CX3CR1 axis influences cell adhesion, apoptosis, and migration, contributing to both pro- and anti-tumor effects. Inflammation and angiogenesis are closely linked, with chronic inflammation promoting angiogenesis through hypoxia and cytokine release. The CX3CL1/CX3CR1 axis enhances this process by activating signaling pathways such as NF-κB, PI3K/Akt, and MAPK, which regulate angiogenesis and tumor growth. The CX3CR1 receptor is expressed in various cell types, including immune cells and endothelial cells, and its activity is modulated by factors such as NF-κB, which controls CX3CL1 expression. The interplay between inflammation and angiogenesis is complex, with CX3CL1/CX3CR1 signaling playing a pivotal role in both processes. Dysregulation of this axis can lead to pathological conditions, including cancer metastasis and poor prognosis. Understanding the mechanisms of CX3CL1/CX3CR1 signaling is essential for developing therapeutic strategies targeting inflammation and tumor progression.